JP2019141065A - 筋細胞パッチおよびその使用 - Google Patents
筋細胞パッチおよびその使用 Download PDFInfo
- Publication number
- JP2019141065A JP2019141065A JP2019071159A JP2019071159A JP2019141065A JP 2019141065 A JP2019141065 A JP 2019141065A JP 2019071159 A JP2019071159 A JP 2019071159A JP 2019071159 A JP2019071159 A JP 2019071159A JP 2019141065 A JP2019141065 A JP 2019141065A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- construct
- contractile
- heart
- cardiomyocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3826—Muscle cells, e.g. smooth muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/367—Muscle tissue, e.g. sphincter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3873—Muscle tissue, e.g. sphincter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1315—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from cardiomyocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
Abstract
Description
本願は、参照によりその全体が本明細書に援用される、2013年10月9日出願の米国仮特許出願第61/888882号の優先権を主張する。
本発明は、VAによって与えられた助成金番号1−101−BX001406−01A1の下で政府支援によってなされたものである。
(a)線維芽細胞含を含む3次元足場(3DFCS)の表面上に未成熟収縮細胞を播種して、収縮構築物を生成することと、
(b)条線を形成する成熟収縮細胞への未成熟収縮細胞の分化を促進する条件下で収縮構築物を培養することと、
を含む方法を提供する。
・形態学的に小さい細胞サイズ;
・筋原繊維密度の減少;
・電気生理学的に抑えられ/減少した活動電位振幅;
・MYH7(ベータミオシン重鎖)、MYH6(アルファミオシン重鎖)、SCN5A、GJA1(コネキシン43)、HCN4(過分極活性化K+チャネル)、KCNJ2(内向き整流性カリウムイオンチャネル)、SERCA2a(サルコ/小胞体(sarcoendoplasmic reticulum)ATPアーゼ)、アルファアクチニン、心臓トロポニンI(cTnI)、心臓トロポニンT(cTnT)の遺伝子および/またはタンパク質の発現の減少。
・形態学的に小さい細胞サイズ;
・筋原繊維密度の減少;
・電気生理学的に抑えられ/減少した活動電位振幅;
・MYH7(ベータミオシン重鎖)、MYH6(アルファミオシン重鎖)、SCN5A、GJA1(コネキシン43)、HCN4(過分極活性化K+チャネル)、KCNJ2(内向き整流性カリウムイオンチャネル)、SERCA2a(サルコ/小胞体ATPアーゼ)、アルファアクチニン、心臓トロポニンI(cTnI)、心臓トロポニンT(cTnT)の遺伝子および/またはタンパク質の発現の減少。
クラスI:いかなる活動でも制約を経験しない;通常の活動からの症状はない。
クラスII:活動にわずかに軽い制約がある;患者は安静時または軽度の労作時に快適である。
クラスIII:いかなる活動でも顕著な制約がある;患者は安静時にのみ快適である。
クラスIV:いかなる身体活動も不快感をもたらし、安静時に症状が起こる。
(a)収縮構築物を生成するための線維芽細胞含を含む3次元足場(3DFCS)の表面上に未成熟収縮細胞を播種することと、
(b)条線を形成する成熟収縮細胞への未成熟収縮細胞の分化を促進する条件下で、収縮構築物を培養することと、
を含む方法を提供する。
パッチの製造
播種方法
簡単に説明すると、懸濁液中の細胞に遠心力を適用する。3次元線維芽細胞構築物(3DFC)の表面上に細胞を押しやる/強いると、細胞をランダムだが均一に分布できる。ベースの構築物(3DFC)が細胞の移植および配置のための支持体ならびに適切な要件を提供すると、収縮力が生じる。最終「生成物」は、線維芽細胞が埋め込まれ、収縮細胞集団、この調製ではiPSC由来の(「未成熟」)心筋細胞が播種された分解性メッシュである。
誘導性ヒト多能性幹細胞(hiPSC)の播種密度は、0.3×106細胞/cm2〜2.4×106細胞/cm2の範囲であり、1.2×106細胞/cm2が理想である。
心臓パッチ用の出発材料は、ヒト皮膚線維芽細胞が埋め込まれた合成ビクリルメッシュを含む3DFCである。線維芽細胞は血管新生を示し、したがって、心臓への移植後、播種されたiPSC由来の心筋細胞集団に栄養サポートを提供する。発明者らのデータは、細胞比(皮膚線維芽細胞に対するiPSC由来の心筋細胞)が3:20〜1.2:1の範囲であり、1.2:2が理想であることを示している。
1. Thai, H. M., Juneman, E., Lancaster, J., Hagerty, T., Do, R., Castellano, L., Kellar, R., Williams, S., Sethi, G., Schmelz, M., Gaballa, M., & Goldman, S. (2009). Implantation of a three-dimensional fibroblast matrix improves left ventricular function and blood flow after acute myocardial infarction. Cell Transplant., 18(3), 283-295. PMC2739416:PM19558777. doi:10.3727/096368909788535004
2. Lancaster, J., Juneman, E., Hagerty, T., Do, R., Hicks, M., Meltzer, K., Standley, P., Gaballa, M., Kellar, R., Goldman, S., & Thai, H. (2010). Viable fibroblast matrix patch induces angiogenesis and increases myocardial blood flow in heart failure after myocardial infarction. Tissue Eng.Part A., 16(10), 3065-3073. PM20486785. doi:10.1089/ten.TEA.2009.0589
3. Lancaster, J. J., Arnce, S. A., Johnson, N. M., Juneman, E. B., Thai, H. M., Kellar, R. S., Vitorin, J. E., Burt, J. M., Bahl, J. J., & Goldman, S. (2010). In vivo evaluation of a biologically active cardiomyocyte seeded scaffold to treat chronic heart failure. [abstract]. Paper presented at the Heart Failure Society of America: 14th Annual Scientific Meeting, San Diego,CA. , 16(8) S45. doi:10.1016/j.cardfail.2010.06.155
4. Lancaster, J. J., Arnce, S. A., Johnson, N. M., Juneman, E. B., Thai, H. M., Kellar, R. S., Vitorin, J. E., Burt, J. M., Gaballa, M. A., Bahl, J. J., & Goldman, S. Tissue engineered scaffold seeded with cardiomyocytes improves cardiac function in rats with chronic ischemic heart failure disease. (Journal of Heart and Lung Transplantation).
・形態学的に小さい細胞サイズ;
・筋原繊維密度の減少;
・電気生理学的に抑えられ/減少した活動電位振幅;
・MYH7(ベータミオシン重鎖)、MYH6(アルファミオシン重鎖)、SCN5A、GJA1(コネキシン43)、HCN4(過分極活性化K+チャネル)、KCNJ2(内向き整流性カリウムイオンチャネル)、SERCA2a(サルコ/小胞体ATPアーゼ)、アルファアクチニン、心臓トロポニンI(cTnI)、心臓トロポニンT(cTnT)の遺伝子および/またはタンパク質の発現の減少。
Claims (1)
- 収縮構築物を調製するための方法であって、
(a)線維芽細胞含を含む3次元足場(3DFCS)の表面上に未成熟収縮細胞を播種して、収縮構築物を生成することと、
(b)条線を形成する成熟収縮細胞への未成熟収縮細胞の分化を促進する条件下で前記収縮構築物を培養することと、
を含む方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021084104A JP2021121206A (ja) | 2013-10-09 | 2021-05-18 | 筋細胞パッチおよびその使用 |
JP2023106221A JP2023123733A (ja) | 2013-10-09 | 2023-06-28 | 筋細胞パッチおよびその使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361888882P | 2013-10-09 | 2013-10-09 | |
US61/888,882 | 2013-10-09 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016547972A Division JP6509882B2 (ja) | 2013-10-09 | 2014-10-08 | 筋細胞パッチおよびその使用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021084104A Division JP2021121206A (ja) | 2013-10-09 | 2021-05-18 | 筋細胞パッチおよびその使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019141065A true JP2019141065A (ja) | 2019-08-29 |
Family
ID=52813614
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016547972A Active JP6509882B2 (ja) | 2013-10-09 | 2014-10-08 | 筋細胞パッチおよびその使用 |
JP2019071159A Pending JP2019141065A (ja) | 2013-10-09 | 2019-04-03 | 筋細胞パッチおよびその使用 |
JP2021084104A Pending JP2021121206A (ja) | 2013-10-09 | 2021-05-18 | 筋細胞パッチおよびその使用 |
JP2023106221A Pending JP2023123733A (ja) | 2013-10-09 | 2023-06-28 | 筋細胞パッチおよびその使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016547972A Active JP6509882B2 (ja) | 2013-10-09 | 2014-10-08 | 筋細胞パッチおよびその使用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021084104A Pending JP2021121206A (ja) | 2013-10-09 | 2021-05-18 | 筋細胞パッチおよびその使用 |
JP2023106221A Pending JP2023123733A (ja) | 2013-10-09 | 2023-06-28 | 筋細胞パッチおよびその使用 |
Country Status (7)
Country | Link |
---|---|
US (3) | US10172976B2 (ja) |
EP (1) | EP3055028B1 (ja) |
JP (4) | JP6509882B2 (ja) |
AU (1) | AU2014331947B2 (ja) |
CA (1) | CA2927062A1 (ja) |
MX (1) | MX2016004616A (ja) |
WO (1) | WO2015054383A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016183143A1 (en) * | 2015-05-11 | 2016-11-17 | The Trustees Of Columbia University Inthe City Of New York | Engineered adult-like human heart tissue |
WO2018013851A1 (en) | 2016-07-13 | 2018-01-18 | The Trustees Of Columbia University | Bioreactor system for engineering tissues |
SG11201912185XA (en) | 2017-06-16 | 2020-01-30 | Avery Therapeutics Inc | Three dimensional tissue compositions and methods of use |
CA3068989A1 (en) * | 2017-07-07 | 2019-01-10 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for improving cardiac function |
US11649424B2 (en) | 2017-07-28 | 2023-05-16 | The Trustees Of Columbia University In The City Of New York | Smart micro bioreactor platform for high throughput mechanical stimulation of cardiac microtissue |
US20210215674A1 (en) * | 2018-05-18 | 2021-07-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for screening compounds for cardiac side effects |
CN111787959A (zh) * | 2018-07-27 | 2020-10-16 | 国立大学法人长崎大学 | 用于消化道再生的片状细胞培养物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06503810A (ja) * | 1990-08-30 | 1994-04-28 | ザ ジェネラル ホスピタル コーポレーション | 移植された組織の拒絶反応を阻害する方法 |
JP2008518998A (ja) * | 2004-11-05 | 2008-06-05 | ノヴォソム アクチェンゲゼルシャフト | 活性物質としてオリゴヌクレオチドを含む医薬組成物におけるまたはそれに関する改善 |
US20080145344A1 (en) * | 2002-10-18 | 2008-06-19 | Reliance Life Sciences Pvt. Ltd. | Three-dimensional tissue equivalent using macromass culture |
JP2011050385A (ja) * | 2001-07-12 | 2011-03-17 | Geron Corp | ヒト多能性幹細胞から産生される心筋細胞系譜の細胞 |
WO2012117855A1 (ja) * | 2011-02-28 | 2012-09-07 | ナパジェン ファーマ,インコーポレテッド | 核酸多糖複合体 |
JP2012523238A (ja) * | 2009-04-09 | 2012-10-04 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ | 三次元繊維芽細胞構築物の細胞播種および共培養 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090169521A1 (en) | 2007-12-31 | 2009-07-02 | Technion Research & Development Foundation Ltd. | Vascularized cardiac tissue and methods of producing and using same |
WO2013056019A1 (en) * | 2011-10-12 | 2013-04-18 | The Trustees Of The University Of Pennsylvania | In vitro microphysiological system for high throughput 3d tissue organization and biological function |
-
2014
- 2014-10-08 EP EP14852537.1A patent/EP3055028B1/en active Active
- 2014-10-08 AU AU2014331947A patent/AU2014331947B2/en active Active
- 2014-10-08 US US15/028,606 patent/US10172976B2/en active Active
- 2014-10-08 JP JP2016547972A patent/JP6509882B2/ja active Active
- 2014-10-08 CA CA2927062A patent/CA2927062A1/en active Pending
- 2014-10-08 MX MX2016004616A patent/MX2016004616A/es unknown
- 2014-10-08 WO PCT/US2014/059688 patent/WO2015054383A1/en active Application Filing
-
2018
- 2018-12-20 US US16/228,017 patent/US11020510B2/en active Active
-
2019
- 2019-04-03 JP JP2019071159A patent/JP2019141065A/ja active Pending
-
2021
- 2021-05-18 JP JP2021084104A patent/JP2021121206A/ja active Pending
- 2021-06-01 US US17/335,687 patent/US11980698B2/en active Active
-
2023
- 2023-06-28 JP JP2023106221A patent/JP2023123733A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06503810A (ja) * | 1990-08-30 | 1994-04-28 | ザ ジェネラル ホスピタル コーポレーション | 移植された組織の拒絶反応を阻害する方法 |
JP2011050385A (ja) * | 2001-07-12 | 2011-03-17 | Geron Corp | ヒト多能性幹細胞から産生される心筋細胞系譜の細胞 |
US20080145344A1 (en) * | 2002-10-18 | 2008-06-19 | Reliance Life Sciences Pvt. Ltd. | Three-dimensional tissue equivalent using macromass culture |
JP2008518998A (ja) * | 2004-11-05 | 2008-06-05 | ノヴォソム アクチェンゲゼルシャフト | 活性物質としてオリゴヌクレオチドを含む医薬組成物におけるまたはそれに関する改善 |
JP2012523238A (ja) * | 2009-04-09 | 2012-10-04 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ | 三次元繊維芽細胞構築物の細胞播種および共培養 |
WO2012117855A1 (ja) * | 2011-02-28 | 2012-09-07 | ナパジェン ファーマ,インコーポレテッド | 核酸多糖複合体 |
Also Published As
Publication number | Publication date |
---|---|
AU2014331947B2 (en) | 2020-02-13 |
US20160250384A1 (en) | 2016-09-01 |
AU2014331947A1 (en) | 2016-05-05 |
JP2021121206A (ja) | 2021-08-26 |
US11020510B2 (en) | 2021-06-01 |
JP2023123733A (ja) | 2023-09-05 |
US20210290823A1 (en) | 2021-09-23 |
US20190142999A1 (en) | 2019-05-16 |
EP3055028A4 (en) | 2017-04-05 |
JP6509882B2 (ja) | 2019-05-08 |
EP3055028A1 (en) | 2016-08-17 |
CA2927062A1 (en) | 2015-04-16 |
JP2016536103A (ja) | 2016-11-24 |
WO2015054383A1 (en) | 2015-04-16 |
US11980698B2 (en) | 2024-05-14 |
MX2016004616A (es) | 2017-01-16 |
US10172976B2 (en) | 2019-01-08 |
EP3055028B1 (en) | 2024-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11980698B2 (en) | Muscle cell patches and uses therefor | |
US20220306992A1 (en) | Cellular seeding and co-culture of a three dimensional fibroblast construct | |
US10004602B2 (en) | Bioactive implant for myocardial regeneration and ventricular chamber restoration | |
ES2540242T3 (es) | Estructura tridimensional de tejido | |
Chachques et al. | Treatment of heart failure with autologous skeletal myoblasts | |
JP2023171773A (ja) | 心臓機能を改善するための組成物および方法 | |
US20210215674A1 (en) | Compositions and methods for screening compounds for cardiac side effects | |
US20200330646A1 (en) | Scaffolds having material properties optimized for cardiac applications and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190424 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200814 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210119 |